Logo

Batting Eyelashes and All

May 27, 2008

Japan's biggest drug maker is making eyes at the US market as its patents get closer to their expiration dates. Takeda Pharmaceutical said it would pay $100 million to be Alnylam Pharmaceuticals' strategic partner in RNAi therapeutics, says the Wall Street Journal. Under this five-year agreement, Takeda will have the right to first negotiation to develop Alnylam products for the Asian market and Alnylam would have the option to develop Takeda's programs in the US.

Breaking News
The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.